Summary
Global Market Direct’s pharmaceuticals report, “S*BIO Pte - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- S*BIO Pte - company overview including business description, key employees, and other facts.
- Review of current pipeline of S*BIO Pte human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of S*BIO Pte with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the S*BIO Pte’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate S*BIO Pte’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of S*BIO Pte in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the S*BIO Pte’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with S*BIO Pte.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of S*BIO Pte and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
Global Market Direct’s pharmaceuticals report, “S*BIO Pte - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- S*BIO Pte - company overview including business description, key employees, and other facts.
- Review of current pipeline of S*BIO Pte human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of S*BIO Pte with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the S*BIO Pte’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate S*BIO Pte’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of S*BIO Pte in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the S*BIO Pte’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with S*BIO Pte.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of S*BIO Pte and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 S*BIO PTE SNAPSHOT
3.1 Business Description
4 S*BIO PTE- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 S*BIO PTE- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 S*BIO PTE PIPELINE PRODUCTS GLANCE
6.1 S*BIO Pte Phase II Pipeline
6.2 S*BIO Pte Phase I Pipeline
6.3 S*BIO Pte Pre-Clinical Pipeline
7 S*BIO PTE - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 S*BIO PTE PIPELINE ANALYSIS
8.1 S*BIO Pte Pipeline Products by Therapeutic Class
8.2 S*BIO Pte Pipeline Products by Target
8.3 S*BIO Pte Pipeline by Route of Administration
8.4 S*BIO Pte Pipeline Products by Molecule Type
9 S*BIO PTE- RECENT PIPELINE UPDATES
10 S*BIO PTE- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 S*BIO PTE- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 S*BIO PTE – FEATURED NEWS
13 S*BIO PTE STATEMENT
13.1 S*BIO Pte - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: S*BIO Pte - Key Information
Table 2: S*BIO Pte - Key Facts
Table 3: S*BIO Pte - Key Therapeutic Areas
Table 4: S*BIO Pte - Pipeline by Stage of Development,
Table 5: S*BIO Pte - Monotherapy Products in Pipeline,
Table 6: S*BIO Pte - Combination Treatment Modalities in Pipeline,
Table 7: S*BIO Pte - Phase II Pipeline,
Table 8: S*BIO Pte - Phase I Pipeline,
Table 9: S*BIO Pte - Pre-Clinical Pipeline,
Table 10: S*BIO Pte - Pipeline By Therapeutic Class
Table 11: S*BIO Pte - Pipeline By Target
Table 12: S*BIO Pte - Pipeline By Route of Administration
Table 13: S*BIO Pte - Pipeline By Molecule Type
Table 14: S*BIO Pte - Recent Pipeline Updates
Table 15: S*BIO Pte - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: S*BIO Pte - Research and Development Overview
Figure 2: S*BIO Pte - Pipeline by Stage of Development,
Figure 3: S*BIO Pte - Monotherapy Products in Pipeline,
Figure 4: S*BIO Pte - Combination Treatment Modalities in Pipeline,
Figure 5: S*BIO Pte - Pipeline By Therapeutic Class and Stage of Development
Figure 6: S*BIO Pte - Pipeline By Therapeutic Class
Figure 7: S*BIO Pte - Pipeline By Target and Stage of Development
Figure 8: S*BIO Pte - Pipeline By Target
Figure 9: S*BIO Pte - Pipeline By Route of Administration and Stage of Development
Figure 10: S*BIO Pte - Pipeline By Route of Administration
Figure 11: S*BIO Pte - Pipeline By Molecule Type and Stage of Development
Figure 12: S*BIO Pte - Pipeline By Molecule Type
COMPANIES MENTIONED
S*BIO Pte
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 S*BIO PTE SNAPSHOT
3.1 Business Description
4 S*BIO PTE- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 S*BIO PTE- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 S*BIO PTE PIPELINE PRODUCTS GLANCE
6.1 S*BIO Pte Phase II Pipeline
6.2 S*BIO Pte Phase I Pipeline
6.3 S*BIO Pte Pre-Clinical Pipeline
7 S*BIO PTE - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 S*BIO PTE PIPELINE ANALYSIS
8.1 S*BIO Pte Pipeline Products by Therapeutic Class
8.2 S*BIO Pte Pipeline Products by Target
8.3 S*BIO Pte Pipeline by Route of Administration
8.4 S*BIO Pte Pipeline Products by Molecule Type
9 S*BIO PTE- RECENT PIPELINE UPDATES
10 S*BIO PTE- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 S*BIO PTE- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 S*BIO PTE – FEATURED NEWS
13 S*BIO PTE STATEMENT
13.1 S*BIO Pte - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: S*BIO Pte - Key Information
Table 2: S*BIO Pte - Key Facts
Table 3: S*BIO Pte - Key Therapeutic Areas
Table 4: S*BIO Pte - Pipeline by Stage of Development,
Table 5: S*BIO Pte - Monotherapy Products in Pipeline,
Table 6: S*BIO Pte - Combination Treatment Modalities in Pipeline,
Table 7: S*BIO Pte - Phase II Pipeline,
Table 8: S*BIO Pte - Phase I Pipeline,
Table 9: S*BIO Pte - Pre-Clinical Pipeline,
Table 10: S*BIO Pte - Pipeline By Therapeutic Class
Table 11: S*BIO Pte - Pipeline By Target
Table 12: S*BIO Pte - Pipeline By Route of Administration
Table 13: S*BIO Pte - Pipeline By Molecule Type
Table 14: S*BIO Pte - Recent Pipeline Updates
Table 15: S*BIO Pte - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: S*BIO Pte - Research and Development Overview
Figure 2: S*BIO Pte - Pipeline by Stage of Development,
Figure 3: S*BIO Pte - Monotherapy Products in Pipeline,
Figure 4: S*BIO Pte - Combination Treatment Modalities in Pipeline,
Figure 5: S*BIO Pte - Pipeline By Therapeutic Class and Stage of Development
Figure 6: S*BIO Pte - Pipeline By Therapeutic Class
Figure 7: S*BIO Pte - Pipeline By Target and Stage of Development
Figure 8: S*BIO Pte - Pipeline By Target
Figure 9: S*BIO Pte - Pipeline By Route of Administration and Stage of Development
Figure 10: S*BIO Pte - Pipeline By Route of Administration
Figure 11: S*BIO Pte - Pipeline By Molecule Type and Stage of Development
Figure 12: S*BIO Pte - Pipeline By Molecule Type
COMPANIES MENTIONED
S*BIO Pte
